Wanbury has officially announced the strengthening of its well-known Coriminic brand through strategic pediatric-focused product launches, as disclosed under Regulation 30 of SEBI listing requirements. The pharmaceutical company has introduced two specialized formulations designed to address regulatory restrictions while maintaining effective treatment options for children's cold and respiratory symptoms.

Product Launch Details

The company's latest regulatory filing reveals the launch of two key products targeting the pediatric healthcare segment:

Regulatory Response Strategy

Wanbury's product development strategy directly responds to recent advisories and regulatory restrictions issued by the Drugs Controller General of India (DCGI). The regulatory body has limited the use of fixed-dose combinations containing Chlorpheniramine + Phenylephrine in children below 4 years due to safety concerns. The company has positioned these new formulations as a first-of-its-kind India-focused initiative to reposition Chlorpheniramine in a safer, indication-driven format for pediatric use.

Key Product Benefits

Coriminic CPM Drops offers several advantages for pediatric care:

Market Positioning

The strategic launch positions Wanbury to capture a significant share of the ₹861 crore Cold Preparation Liquid market while navigating the restrictions laid by DCGI. Coriminic NS Nasal Drops serves as a non-systemic nasal decongestant solution, providing localized relief for children from nasal congestion and helping physicians navigate treatment options within government regulatory boundaries.

Strategic Impact

With this expansion, Wanbury is poised to further consolidate its presence in the fast-growing children Cold Preparation Liquid market. The company's approach demonstrates its commitment to addressing healthcare needs in the regulated children's medicine segment while maintaining compliance with evolving regulatory requirements in the pediatric pharmaceutical space.

Wanbury Limited has announced significant regulatory approvals, including Sertraline Form II clearance from ANVISA Brazil and special grade Metformin DC approval from a major customer. The pharmaceutical company disclosed these developments through an official filing under Regulation 30 of SEBI listing requirements.

ANVISA Brazil Approves Sertraline Form II

The company has received approval from ANVISA Brazil for Sertraline Form II, adding to its existing Sertraline hydrochloride Form I approval. This regulatory milestone strengthens Wanbury's position in the Brazilian pharmaceutical market:

According to the company's regulatory filing, the Form II approval will help in further consolidation of Wanbury's share of business in the Brazilian market, where it already maintains a dominant position.

Special Grade Metformin DC Approval

Wanbury has secured approval from one of its largest customers for special grade Metformin DC, representing a significant revenue opportunity:

Manufacturing Compliance Maintained

The company confirmed that both its API manufacturing sites at Patalganga and Tanuku continue to remain compliant with cGMP Rules and Regulations. This compliance status supports the company's ability to manufacture and supply the newly approved products while maintaining regulatory standards across its operations.

Strategic Business Impact

These dual approvals represent important regulatory milestones for Wanbury's pharmaceutical business. The Sertraline Form II approval from ANVISA Brazil leverages the company's existing market leadership position, while the special grade Metformin DC approval opens a new revenue stream with substantial annual potential. The combination strengthens Wanbury's product portfolio and market presence in key therapeutic segments.